The laboratory is working on understanding the molecular mechanisms by which acute lymphoblastic leukemia cells survive extensive chemotherapy. We are engaged in several projects using a combination of genetic, bioinformatics and biochemical tools to analyze the functions of specific target proteins and their role in the pathogenesis of acute lymphoblastic leukemia. The goal of our research is to uncover the underlying mechanisms of therapy resistance and to develop less toxic, highly effective molecularly-targeted therapies against acute lymphoblastic leukemia. The lab is mainly focusing on childhood leukemia as this group of patients suffers from long-term side effect of the current therapies.
Read more about us @ Lund University
Kazi J. U. and Rönnstrand L. (2019) FMS-like tyrosine kinase 3/ FLT3: from basic science to clinical implications. Physiological Reviews, 99(3):1433-1466 (Pubmed, Link, Lund University, ResearchGate).
Chougule R. A., Shah K., Moharram S. A., Vallon-Christersson J. and Kazi J. U. (2019) Glucocorticoid-resistant B-cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. npj Genomic Medicine 4:7 (Pubmed, Link, Lund University, ResearchGate).
Moharram S.A., Shah K., Khanum F., Rönnstrand L. and Kazi J.U. (2019) The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer Journal, 9:5. (Pubmed, Link, Lund University, ResearchGate).
Kazi J.U. and Rönnstrand L. (2019) The role of SRC family kinases in FLT3 signaling. International Journal of Biochemistry & Cell Biology, 107(1) 32-37. (Pubmed, Link, Lund University, ResearchGate) Review.
Li T., Deng Y., Shi Y., Tian R., Chen Y., Zou L., Kazi J.U., Rönnstrand L., Feng B., Chan S. O., Chan W. Y., Sun J. and Zhao H. (2018) Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37(47):6180-6194. (Pubmed, Link, Lund University, ResearchGate).
Shah K., Moharram S. A. and Kazi J.U. (2018) Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. Clinical Epigenetics 10: 83 (Pubmed, Link, Lund University, ResearchGate).